GleamWall
中文EN

NTRR NEUTRA CORP.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1512886 · Fiscal year ends 01/31

Financial factors as of 2023-10-31 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-82.7%
TTM net income YoY-2.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin46.2%
Operating margin-1,457.1%
Net margin-2,723.6%
FCF margin—
EBITDA margin-1,103.4%

Returns

ROE—
ROA-758.7%
ROIC (approx.)—
Asset turnover0.28x

Leverage & solvency

Liabilities / assets3,574.0%
Debt / equity—
Current ratio0.02x
Interest coverage-14.07x

Cash quality & payout

Operating cash flow / net income0.02x
Accruals ratio-743.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2024Q32023-10-312024Q22023-07-312024Q12023-04-302023Q4*2023-01-312023Q32022-10-312023Q22022-07-312023Q12022-04-302022Q4*2022-01-31
Income statement
Revenue$1,311$4,325$5,842$5,919$23,383$29,032$9,662$38,383
Cost of revenue$722$2,643$3,038$2,965$12,708$12,479$4,538$9,639
Gross profit$589$1,682$2,804$2,954$10,675$16,553$5,124$28,744
SG&A expense$43,487$57,817$50,781$41,016$46,439$65,018$75,501$155,080
Operating income-$52,728-$71,769-$71,208-$57,789-$66,074-$82,350-$91,462-$160,668
Interest expense$2,258$29$199$15,535$15,718$15,076$15,734$15,105
Pretax income-$54,986-$71,798-$71,407-$271,480-$81,792-$97,426-$107,196—
Income tax$0$49$589—————
Net income-$54,986-$71,847-$71,996-$275,003-$81,792-$97,426-$107,196-$175,773
EBITDA-$43,677-$58,730-$51,482-$38,062-$46,348-$62,623-$71,736-$140,941
EPS (diluted)————————
Balance sheet
Cash & equivalents$692$1,134$3,138$1,969$456$26,325$15,188$1,056
Receivables$98———————
Inventory$18,610$19,213$21,332$23,846$26,810$25,108$21,991—
Current assets$19,400$20,347$24,470$25,815$28,876$53,043$38,789$2,666
PP&E, net$7,544$16,595$29,634$49,360$69,087$88,813$108,540$128,266
Total assets$26,944$36,942$54,104$75,175$97,963$141,856$147,329$130,932
Current liabilities$908,828$863,840$809,155$759,639$1.25M$1.21M$1.21M$1.15M
Total liabilities$962,984$917,996$863,311$813,795$1.30M$1.26M$1.22M$1.15M
Shareholders' equity-$936,040-$881,054-$809,207-$773,820-$1.26M-$1.18M-$1.11M-$1.27M
Shares outstanding2.92B2.92B2.92B2.74B2.30B2.30B2.21B1.78B
Cash flow statement
Operating cash flow-$442-$2,004-$8,831$1,513-$23,225-$38,863-$92,668-$53,002
Capital expenditure———————$0
Free cash flow———————-$53,002
Investing cash flow———————$0
Financing cash flow$0$0$10,000$0-$2,644$50,000$106,800$25,000
Depreciation & amortization$9,051$13,039$19,726$19,727$19,726$19,727$19,726$19,727

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.